Mirum Pharmaceuticals Inc (NAS:MIRM)
$ 32.05 0.91 (2.92%) Market Cap: 1.51 Bil Enterprise Value: 1.47 Bil PE Ratio: 0 PB Ratio: 6.42 GF Score: 44/100

Mirum Pharmaceuticals Inc To Discuss The Topline Data From the MARCH Study Call Transcript

Oct 24, 2022 / 01:00PM GMT
Release Date Price: $20.02 (+2.56%)
Operator

Hello, and a warm welcome to the Mirum Phase III Top Line Results Conference Call. My name is Candice, and I'll be your moderator for today's call. (Operator Instructions)

I would now like to pass you over to our host for today's call, Ian Clements, CFO. Please go ahead.

Ian Clements
Mirum Pharmaceuticals, Inc. - CFO

Thanks, Candice, and good morning, everyone. I'd like to welcome you to Mirum's MARCH-PFIC Phase III top line results conference call. I'm joined today by President and CEO, Chris Peetz; Head of R&D, Pam Vig, Chief Development Officer, Lara Longpre; and Chief Operating Officer, Peter Radovich. Earlier this morning, Mirum issued a news release announcing positive results from our Phase III MARCH study. Copies of the news release can be found in the IR section of our website. Also in the IR section of our website, you can find a slide deck outlining results in this study. We will refer to this deck as we go through the results this morning.

Before we begin, I'd like to remind you that during the course of this conference call,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot